Bisphosphonate therapy in multiple myeloma: past, present, future
Author:
Open Access
- 1 November 2002
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 69 (5-6) , 257-264
Abstract
Bone disease characterised by osteolytic lesions, pathological fractures and hypercalcaemia is an important clinical feature in multiple myeloma. Pain, decreased performance status, and the need for palliative radiotherapy and surgical interventions are common sequelae. Bisphosphonates act primarily on osteoclasts to inhibit excessive bone resorption, and have therefore been investigated in myeloma patients to ameliorate the clinical consequences of the bone disease. Bisphosphonates are currently the therapy of choice in myeloma patients with hypercalcaemia. In long‐term management, both oral clodronate and intravenous pamidronate are effective in reducing skeletal‐related events. Zoledronic acid seems to be as effective as pamidronate. Whether bisphosphonates have antimyeloma activity is currently unknown. Cost–benefit analyses have shown reasonable efficacy with acceptable costs. Bisphosphonate therapy is now accepted as an important part of care in myeloma patients, although much still has to be learned in order to optimise this therapy in multiple myeloma.Keywords
This publication has 85 references indexed in Scilit:
- The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple MyelomaDrugs, 2001
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998
- Pyridinium cross-links in multiple myeloma: Correlation with clinical parameters and use for monitoring of intravenous clodronate therapy—A pilot study of the German Myeloma Treatment Group (GMTG)European Journal of Cancer, 1996
- Monitoring the action of clodronate with type I collagen metabolites in multiple myelomaEuropean Journal of Cancer, 1996
- ClodronateDrugs, 1994
- Serum osteocalcin in the management of myelomaEuropean Journal of Cancer, 1993
- BisphosphonatesDrugs, 1991
- PamidronateDrugs, 1991
- Long-Term Effects of Dichloromethylene Diphosphonate (Cl2 DP) on skeletal Lesions in Multiple MyelomaMetabolic Bone Disease and Related Research, 1982
- Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple MyelomaNew England Journal of Medicine, 1980